Posts for Ticker ‘ACAD’

Top 10 Pre-Market Analyst Calls (ACAD, ACE, AACC, RATE, GYMB, KIM, MMC, MVL, NCR, WSH)

These aren’t all of the analyst calls out there today, but these are ten of the calls impacting shares early this Tuesday morning:

  • ACADIA Pharmaceuticals (ACAD) Raised to Neutral at Banc of America.
  • ACE Limited (ACE) Raised to Outperform at Wachovia.
  • Asset Acceptance Capital (AACC) Cut to Underperform at Jefferies.
  • Bankrate (RATE) Cut to Hold from Buy at Collins Stewart.
  • Gymboree (GYMB) Cut to Market Perform from Outperform at FBR.
  • Kimco Realty (KIM) Cut to Neutral from Outperform at Credit Suisse.
  • Marsh & McLennan (MMC) Raised to Buy from Hold at Citigroup.
  • Marvel Entertainment (MVL) Started as Market Weight at Thomas Weisel.
  • NCR (NCR) Raised to Outperform from Neutral at Baird.
  • Willis Group (WSH) Cut to Hold at Citigroup.

Jon C. Ogg
July 8, 2008

Posted on: July 8, 2008 – 6:29 am in Analyst Calls, , , , , , , , , ,

The 52-Week Low Club (PPC)(PBG)(RCL)(GHS)(ACAD)

Pilgrim’s Pride (PPC) Downgraded by Credit Suisse. Down to $15.67 from 52-week high of $41.

Pepsi Bottling Group (PBG) Still troubled by problems at one of Coke’s bottlers. Down to $29.22 from 52-week high of $43.38.

Royal Caribbean Cruises (RCL) Getting killed like the rest of the travel industry. Down to $25.40 from 52-week high of $43.96.

Gatehouse (GHS) Analyst encouraging company to drop dividend to save money. Down to $2.79 from 52-week high of $19.60.

Acadia Pharmaceuticals (ACAD) Major drug trial failure. Sharp sell-off to $4.30 from 52-week high of $17.33.

Douglas A. McIntyre

Posted on: June 16, 2008 – 3:00 pm in HI/LOW, , , , ,

Biotech Busine$$ Daily (ACAD, AMLN, CVTX, HALO, KOSN, MCU, NVAX, POZN, REGN, SIRT)

If you thought biotech news was getting quiet going into earnings season, think again.

Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment  for Parkinson’s disease psychosis (PDP) at the 60th American Academy of Neurology Annual Meeting today. According the results from the study, pimavanserin is safe and effective at improving psychosis scores without hindering motor abilities. Shares are up $0.46 to $8.36 on a 52-week range of $7.63 to $17.33.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up almost 3% in mid-morning trading. They announced that the earnings call is schedule for March 21. Trading at $30.42 on a 52-week range of $23.75 to $53.25.

CV Therapeutics, Inc. (NASDAQ: CVTX) soaring today after they announced Tuesday that they will receive $185 milliion from TPG-Axon Capital for rights to the sales of Lexiscan, a drug for patients that are unable to exercise during heart tests and was granted FDA approval last Thursday. Shares are up over 15% to $8.63 on a 52-week range of $5.41 to $13.74.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced pre-clinical findings in combinations of bisphosphonates and rHuPH20 at the American Association for Cancer Reseacrch conference today. The study showed that a combination of these molecules could reduce local irritation from chemotherapy by allowing a subcutaneous route of administration. Shares are up over 10% to $5.99 on a 52-week range of $4.19 to $11.00.

Kosan Biosciences Inc. (NASDAQ: KOSN) is still steadily rising after Monday announcement that Phase II testing for Epothilone KOS-1584 initiated. The drug targets patients with non-small cell lung cancer. Shares are up over 11% to $2.00 today. Monday, shares opened at $1.50. The 52-week range is $1.28 to $6.53.

Medicure Inc. (AMEX: MCU) up by 40% with the announcement that Phase II results for MC-1 and lisinpril for patients with type-II diabetes and hypertension will be presented at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference today. The data from the study was previously released. Shares are up 40% to $0.09 on a 52-week range of $0.05 to $1.64.

Novavax, Inc. (NASDAQ: NVAX) reported positive results in preclinical studies of Trivalent, a seasonal influenza vaccine. Phase II testing is hoped to begin in the third-quarter this year. Shares are up over 5% to $2.51. The 52-week range is $2.24 to $4.38.

Pozen, Inc. (NASDAQ: POZN) skyrocketing today on news that migraine drug Treximet has received FDA approval. They partnered with GlaxoSmithKline (GSK) for development of the drug. It is a follow up for Glaxo’s similar drug, Imitrex, which is set to lose patent protection in 2009. Pozen up 34% to $14.19 on a 52-week range of $8.29 to $19.75. Glaxo is up marginally to $42.57.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) moving higher than the rest today on no new developments. Shares are up $1.37 to $19.60 on a 52-week range of $13.55 to $28.74.

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) published a report by Scientific Advisory Board Co-Chairs that showed first in-vivo data demonstrating that SIRT1 enzymes suppress tumor development in colon cancer cells. Shares are up almost 5% to $12.56 on a 52-week range of $9.50 to $21.99.

Rachel Lopez
April 16, 2008

Posted on: April 16, 2008 – 11:18 am in Biotech, , , , , , , , , ,

Pre-Market Analyst Calls (July 10, 2007)

ACAD started as Outperform at FBR.
ALC started as Outperform at RBC.
ARUN started as Buy at Jefferies.
ATVI started as Buy at First Albany.
AZ raised to Buy at UBS.
CHA cut to Hold at Deutsche Bank.
DRIV raised to Outperform at RBC.
DTV raised to Buy at Citigroup.
EMC started as Mkt Perform at BMO Capital Markets.
F raised to Overweight at JPMorgan.
FOLD started as Overweight at JPMorgan.
FORM cut to Underweight at JPMorgan.
FVE started as Sector Perform at RBC.
GGG cut to Sector Perform at CIBC.
GM raised to Overweight at JPMorgan.
GME started as Buy at First Albany.
GRMN started as Neutral at B of A.
LMIA cut to Mkt Perform at Wachovia.
MU raised to Buy at Jefferies.
PLCM started as Buy at Jefferies.
PNM raised to Hold at Citigroup.
QLGC started as Outperform at BMO Capital Markets.
RACK cut to Sector Perform at RBC.
SMG raised to Overweight at JPMorgan.
UNCA cut to Hold at Jefferies.
VOLV raised to Overweight at HSBC.

Jon C. Ogg
July 10, 2007

Posted on: July 10, 2007 – 6:41 am in Analyst Calls, , , , , , , , , , , , , , , , , ,

Cramer Speculates in CV Therapeutics (CVTX)

On tonight’s Mad Money on CNBC, Jim Cramer had his normal ‘Speculation Friday’ and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech (NSTK).  Cramer said CVTX is a huge battle ground stock that makes small molecule drugs.  Last month it had 36% of the float short, but he thinks the bearish case just doesn’t hold up.  Cramer thinks the stock could explode into the $20’s because of earnings, or it could get acquired and go there.  Its Ranexa drug for angina is the driver now, but it could get approved as a diabetic treatment down the road.  It has a drug up for potential approval next year to detect cardiac disease. Cramer said it could fetch $20.00 to $36.00 per share if it was to be acquired.

Speculators and biotech investors should know that this one does lose money and it is expected to keep losing money: -$2.95 EPS for fiscal 2007 and expected to post -$1.31 in 2008 fiscal EPS.  This stock closed up over 5% today, and shares went up another 6% after-hours and after-Cramer to $12.08.  Its market cap at the close was $675 million and the 52-week trading range is $6.43 to $14.67.  For a history lesson, this has been public since 1997 and shares reached north of $80.00 back in 2000 to 2001.  This is one we can look at from before Cramer gave it the nod, and if we trust a "sometime in 2008 timeframe" then we can look at the JAN-2009 closest out of the money call options, or the $12.50 strike.  These didn’t trade today, but the closing levels looked to be $2.90X$3.20 with only 507 contracts in the open interest.  Also keep in mind that this stock experienced a mini-implosion back in March.

Jon C. Ogg
June 15, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 15, 2007 – 5:45 pm in Biotech, Cramer, , ,

Pre-Market Stock News (June 6, 2007)

(AAUK) Anglo American’s CEO will become a non-executive member of the board of directors at BP (BP).
(ACAD) Acadia Pharmaceuticals traded up over 10% after Jim Cramer touted the stock as a speculative play for trading the upcoming data on its schizophrenia and Parkinson’s treatment.
(ACOR) Acorda Therapeutics Starts Second Phase 3 Trial of Fampridine-SR in MS
(AMTD) TD AMERITRADE was notified that JANA and S.A.C. funds have secured an interest of roughly 8.6% stake to pressure the companies to enter a merger.
(AZN) AstraZeneca CFO leaves to join Goldman Sachs.
(CROX) Crocs is launching a fashionable line of high heel and flats for women to appeal to fashion conscious women.
(CSC) Computer Sciences Corp. may look to acquire iSoft Group plc in the UK.
(ETFC) E*Trade trading up 3% on AMERITRADE news.
(FCS) Fairchild Semiconductor reaffirmed Q2 growth targets.
(GSK) GlaxoSmithkline defends Avandia saying it does not increase heart risks.
(KFY) Korn Ferry $0.37 adjusted EPS versus $0.34 estimates.
(MAIR) MAIR Holdings -$0.06 EPS vs -$0.05e.
(PNRA) Panera trading down $7.00 on an earnings warning of $0.38-0.40 vs $0.47-0.51e.
(PLUG) Plug Power named new CFO.
(PRU) Prudential lays off 420 in a research phase out, will cease covering all equities immediately.
(RUS) Russ Berrie rejected an $18.00 buyout as an undervalued deal.
(SCHW) Charles Schwab traded up 1% after the AMERITRADE news.
(SIRI) Sirius Satellite Radio announced a $250 million term-loan from Morgan Stanley.
(STAR) Starent priced a 10.5 million share IPO at$12.00, above the $9.00 to $11.00 range.
(WFMI) Whole Foods is facing a deal blockage by the FTC over a ‘natural foods market disruption’ according to FTC.

Jon C. Ogg
June 6, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 6, 2007 – 7:13 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , ,

Cramer Backs Acadia Pharmaceuticals (ACAD)

Cramer has a speculative little drug stock that keeps getting thrown to him in the Lightning Round: Acadia Pharmaceuticals (ACAD).  Cramer thinks now is the time that you can buy Acadia.  It trades entirely on expectations and hopes that one of the drugs will pan out.  There is some conviction here, after it has pulled back from its highs.  It has 3 drugs in the pipeline for the treatment of Schizophrenia and Parkinson’s.  None of the drugs can come to market until 2009.  It only has two large brokerage firms, one from Lehman and one from B of A.  It has data on the way and could move this quarter; you can’t wait for the data to come.  Phase II results in the schizophrenia cocktail treatment should be this quarter or next and it could draw a partner.  The parkinsons drug is theirs alone and could have lots of promise.  ACP-104 going to phase IIb that is also going to be indicated for a standalone schizophrenia drug rather than a cocktail.  Cramer said he isn’t waiting for these to get approved, he’s waiting to take profits as positive data.  They had a broken secondary offering that caused shareholder pain from April.

Jon C. Ogg
June 5, 2007

Jon ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 5, 2007 – 6:32 pm in Biotech, Cramer,